Founded in 2015, Genome & Company is a biotechnology firm specializing in immuno-oncology with a focus on developing first-in-class antibody-drug conjugates (ADCs). The company leverages its proprietary GNOCLE platform to discover novel cancer targets and develop them as either standalone antibodies or ADCs, forming a pipeline aimed at global out-licensing.
The company’s lead candidate, 카지노 슬롯 머신 하는 법104, is an immune checkpoint inhibitor that targets CNTN4, a molecule involved in tumor immune evasion. 카지노 슬롯 머신 하는 법104 restores T-cell activity by blocking the CNTN4-APP pathway. Notably, CNTN4 is highly expressed in various solid tumors and is mutually exclusive with PD-L1 expression, indicating potential in patients unresponsive to PD-1/PD-L1 therapies.
In February 2024, Genome & Company licensed 카지노 슬롯 머신 하는 법104 to UK-based Ellipses Pharma, with plans to initiate Phase 1 clinical trials in both the UK and the U.S.
Building on this success, the company developed 카지노 슬롯 머신 하는 법104 ADC, which conjugates the 카지노 슬롯 머신 하는 법104 antibody to a cytotoxic payload. The ADC selectively targets CNTN4-expressing tumor cells, delivers the drug intracellularly, and induces cell death. Preclinical studies demonstrated a 100% tumor suppression rate, supported by strong internalization and antitumor activity in animal models.
In May 2024, 카지노 슬롯 머신 하는 법104 ADC was out-licensed to Swiss biotech Debiopharm in a deal worth up to 0 million, including a .1 million upfront payment.
Beyond the 카지노 슬롯 머신 하는 법104 program, Genome & Company is advancing three additional immuno-oncology candidates—카지노 슬롯 머신 하는 법120, 카지노 슬롯 머신 하는 법121, and 카지노 슬롯 머신 하는 법122—currently in preclinical development via the GNOCLE platform. These assets are being explored as both ADCs and immune antibodies, reinforcing the company’s strategy to expand its first-in-class oncology pipeline.
